Hospira, Inc., has issued a nationwide Vancomycin Injection recall over concerns about the presence of glass particulates in the vials. New York-based Hospira Pharma is affiliated with international ...

Vancomycin (as HCl) 500mg/vial, 1g/vial; lyophilized pwd for IV infusion after reconstitution and dilution. Not for prophylaxis of endophthalmitis. Renal insufficiency. Monitor hearing, blood, renal ...

(RTTNews) - Glenmark Pharmaceuticals Inc., USA, affiliated to India-based Glenmark Pharmaceuticals Ltd., announced Tuesday the launch of Vancomycin Hydrochloride for Injection USP in single-dose vials ...

Ready-to-infuse sepsis therapy marks new advancement in time-critical treatment LONDON, July 2, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today ...

Please provide your email address to receive an email when new articles are posted on . The FDA is warning against the use of prophylactic intraocular vancomycin formulations during cataract surgery ...

TYZAVAN ™ is a glycopeptide antibacterial indicated for the treatment of the following infections in adult and pediatric patients (1 month and older) for whom appropriate dosing with this formulation ...

Please provide your email address to receive an email when new articles are posted on . Intraosseous vancomycin levels were minimally detected at the end of the procedure vs. IV vancomycin levels.

The US Food and Drug Administration (FDA) is issuing a compounding risk warning against intraocular injections of vancomycin either alone or in combination with other drugs, in light of a new case of ...

Details concerning the Vancomycin Hydrochloride Injection medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ointments, ...

Glenmark is introducing vancomycin hydrochloride for injection, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial), which is the generic of Mylan’s Vancomycin Hydrochloride for Injection.

LONDON, July 2, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announced the approval of a novel formulation of the first-of-its-kind, ready-to ...